21-Dec-09

All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization (WHO) for use in developing world

 

 

18-Dec-09

Novartis meningococcal vaccine Menveo® recommended for approval in the European Union for prevention of disease in adolescents and adults

 

 

24-Nov-09

Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility

 

 

17-Nov-09

Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)

 

 

13-Nov-09

Novartis receives approval in Switzerland for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine

 

 

05-Nov-09

Novartis receives regulatory approval in Germany for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine

 

 

06-Oct-09

Novartis completes shipment of US supply of Fluvirin® seasonal influenza vaccine

 

 

25-Sep-09

Novartis A(H1N1) Pandemic Influenza vaccine Focetria® receives positive opinion from CHMP

 

 

03-Sep-09

Novartis MF59® adjuvanted cell culture-based vaccine shows strong immune response in A(H1N1) clinical trials

 

 

05-Aug-09

Novartis begins shipment of Fluvirin® seasonal influenza vaccine for the U.S. market ahead of schedule

 

 

01-Jul-09

Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo®

 

 

12-Jun-09

Novartis successfully demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine

 

 

04-Jun-09

Novartis announces typhoid vaccine research program in partnership with the Wellcome Trust

 

 

26-May-09

Novartis to enter Japan vaccines market through agreement for Haemophilus Influenzae Type B (Hib) vaccine

 

 

30-Apr-09

Novartis investigational adjuvanted (MF59) pre-pandemic avian influenza vaccine Aflunov® shows long lasting, broadly crossprotective immune response
(106 KB)

 

 

28-Apr-09

Dr. Rino Rappuoli, Head of Research for Novartis Vaccines, Honored with Prestigious Albert B. Sabin Gold Medal for Reverse Vaccinology
(59 KB)

 

 

02-Apr-09

Ixiaro® vaccine receives Marketing Authorization in Europe
(56 KB)

 

 

30-Mar-2009

Ixiaro® receives FDA approval for the prevention of Japanese Encephalitis
(70 KB)

 

 

26-Feb-2009

Novartis Vaccines Statement

Following the Medicine and Healthcare Products Regulatory Agency Drug Alert issued at 5pm yesterday Novartis Vaccines continues to work with the MHRA to recall specific lots of the Meningitis C vaccine – Menjugate Kit. These being Lot 236011 and Lot 235012A that were both distributed in the UK.

This is purely a precautionary measure as the lots distributed passed all routine checks before release. However, parents who are still concerned should contact their GP or NHS Direct. Novartis initiated this rapid precautionary recall because patient safety is our utmost concern and we are committed to being a safe and reliable provider of vaccines.

For further information please contact the Novartis Vaccines UK Press Office on:

+44 (0)1276 698567

 

 

15-Jan-2009

US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine